Efficacy and Safety of Siltacelle in Multiple Myeloma Patients

Siltacabdigine autolucil is a CAR T-cell therapy expressing two BCMA targeting single-domain antibodies. In the phase 1B2-cartitude-1 trial, siltacelle induced early, deep and durable responses in heavily pre-treated patients with relapsed refractory multiple myeloma. The overall response rate was 98% at a median follow-up of two years. One duration of response and median progression-free survival were not reached.